This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.
1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors
ePostersLive by SciGen Technologies S.A. All rights reserved.
September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas
ABCL - 1515
Aggressive B-Cell Lymphoma (ABCL)
Breast cancer survivors may experience subsequent lymphoid malignancies, but whether non-Hodgkin lymphoma (NHL) risk differs by breast cancer molecular subtype, anatomic presentation, and latency remains incompletely characterized.
Using SEER Research Plus 17 data from 2010–2022, we evaluated women with a first primary invasive breast cancer and examined subsequent NHL according to nodal versus extranodal presentation, breast cancer molecular subtype, and latency after breast cancer diagnosis. Molecular subtypes included HR+/HER2+, HR−/HER2+, HR+/HER2−, and HR−/HER2−. Standardized incidence ratios (SIRs) with 95% confidence intervals were estimated using MP-SIR methodology across latency intervals of 2–11, 12–59, 60–119, and ≥120 months.
Distinct subtype- and latency-specific patterns emerged. For nodal NHL, both HR+ subtypes demonstrated significantly elevated incidence during the first year after breast cancer diagnosis: HR+/HER2− had the strongest early signal (SIR 1.97, 95% CI 1.71–2.26), while HR+/HER2+ had an SIR of 1.81 (95% CI 1.12–2.77). This early elevation was transient. During 12–59 months, nodal NHL incidence fell below expectation for both HR+/HER2− (SIR 0.79, 95% CI 0.70–0.88) and HR+/HER2+ (SIR 0.65, 95% CI 0.44–0.94).
In contrast, extranodal NHL demonstrated lower-than-expected incidence among HR− subtypes. HR−/HER2+ disease had an overall SIR of 0.27 (95% CI 0.09–0.62), while HR−/HER2− disease demonstrated an SIR of 0.54 (95% CI 0.28–0.94) at 12–59 months and an overall SIR of 0.65 (95% CI 0.43–0.93).
These findings suggest that subsequent NHL after breast cancer is heterogeneous rather than uniform. HR+ breast cancer was characterized by an early, transient elevation in nodal NHL, whereas HR− subtypes demonstrated lower-than-expected extranodal NHL incidence. The findings are hypothesis-generating and do not establish causality. Future survivorship research should consider molecular subtype, anatomic compartment, and time since breast cancer diagnosis rather than treating subsequent NHL as a single pooled outcome